Trial Profile
A Multiple Dose Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered NNC0148-0287 (Insulin 287) in Subjects With Type 2 Diabetes
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin icodec (Primary) ; Insulin degludec
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 05 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 28 Apr 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 May 2015 to 1 Jun 2015.
- 28 Apr 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 May 2015 to 1 Jun 2015.